Organization & Developments: ReCode Therapeutics

Parents

Company advancing its proprietary non-viral lipid nanoparticle (“LNP”) delivery platform for organ-specific delivery of RNA therapies and gene editing components.
ReCode Therapeutics is a development-stage biopharmaceutical company focused on the correction of the nonsense mutations that account for 1/3 of all inherited diseases, including approximately 10% of cystic fibrosis.
ReCode Therapeutics is concentrating on primary ciliary dyskinesia, cystic fibrosis and other diseases of the lung, spleen, liver and central nervous system